How to Buy Neuralink Stocks

How to Buy Neuralink Stocks

Find out if you can buy Neuralink stocks and learn about its groundbreaking advancements in neurotechnology. Stay informed on its future IPO plans and potential impacts.

Summary: Neuralink, led by Elon Musk, remains a private company with no immediate plans for an IPO. Valued at over $1 billion, it relies on private funding. For investments in related fields, consider neurotech and biotech firms like Amgen (AMG) and AstraZeneca (AZN), available via regulated brokers.

Our review suggests eToro, which offers over 3,000 assets, including Amgen, AstraZeneca, and ETFs like ARK Genomic Revolution (ARKG), providing diversified investment opportunities in these advanced sectors.

Content Guide
Top Platform to Buy Neurotech Stocks and ETFs
5.0 out of 5.0 by Datawallet.
eToro stands out as the optimal platform for investing in neurotech stocks and ETFs due to its expansive asset selection, including leading neurotech companies like Amgen, AstraZeneca and 200 others in the medical tech sector.
Deposit Methods
Bank Transfer, SEPA, Debit Card, Credit Card and more.
Supported Assets
3,000 Stocks, ETFs (including Neurotech), Commodities and more.
Licensing and Regulation
FCA, CySEC, FinCEN, ASIC and other Tier-1 Regulators.

74% of retail CFD accounts lose money.

Daily Newsletter & Research  🗞️

Get the daily newsletter keeping 200,000 investors ahead of the market.

Your email been received!
Please double check your email address.

Can I Buy Neuralink Stocks?

No, you can't buy Neuralink stocks yet. Neuralink, started by Elon Musk and top neuroscientists in 2016, is still a private company. It focuses on brain-machine interfaces, blending advanced tech with neuroscience. Currently, Neuralink relies on private investors, with Elon Musk being a major backer. Its technology could revolutionize healthcare and tech sectors, sparking much interest. Investors and industry watchers are closely watching for any signs of Neuralink going public.


Is Neuralink Going to IPO?

Neuralink hasn't announced an IPO date yet. This has generated excitement in the tech and biotech sectors. They're known for creating advanced brain-machine interfaces and aiming to treat neurodegenerative diseases, and even boost human cognition. Despite the buzz, Neuralink stays privately funded for now. They might be eyeing an IPO in the future. Remaining private helps them concentrate on their research without worrying about public shareholders.

Who Owns Neuralink?

Elon Musk, Tesla’s CEO, launched Neuralink in 2016 with an initial $100 million investment. Since then, it has gained substantial private funding. Notably, a recent $205 million Series C round saw investments from Google Ventures, ARCH Venture Partners, Founders Fund, and Sam Altman, the CEO of OpenAI. Despite these investments, Elon Musk remains the majority shareholder of Neuralink.

Who Owns Neuralink

About Neuralink

Neuralink, co-founded by Elon Musk, leads in brain-machine interface tech with its Telepathy Implant. This device, once called the N1 Implant, has 1024 electrodes on 64 ultra-thin threads, implanted using a precision surgical robot. It's encased in biocompatible material and runs on a wirelessly charged battery. This marks a big jump from research to real-world use, letting people control digital devices with their thoughts.

Recently, Neuralink succeeded in implanting Telepathy in a human. The patient is recovering well, and the device shows promising neuron spike detection. Early users, especially those with limb loss, may soon control phones, computers, and other devices by thought. This breakthrough in neural tech could greatly change medical science and human-machine interaction.

Best Neurotech Alternatives to Neuralink

If you’re interested in neurotechnology but find Neuralink’s private status limiting, consider these publicly traded alternatives:

  • Amgen (AMG): A leader in biotechnology. Focuses on neurodegenerative diseases and neurological conditions. Advancements align closely with the neurotech sector.
  • AstraZeneca (AZN): A global pharmaceutical and biotech company. Strong focus on neuroscience. Develops drugs for psychiatric and neurological disorders.
  • ARK Genomic Revolution ETF (ARKG): Offers broader exposure to biotech innovations, including neurotechnology. Provides diversified investments in genomics companies.

You can find these stocks and funds on secure, regulated platforms like eToro. This lets you invest in the growing fields of neurotechnology and medical technology.

Best Neurotech Alternatives to Neuralink

Neuralink Stock Price

Neuralink is privately held, so it doesn't have a publicly traded stock price. Despite this, its valuation has surpassed $1 billion based on fundraising rounds. Those interested should check current sources for the latest info, as financial landscapes and company valuations can change over time.

Bottom Line

In summary, Neuralink is a private company, making its stocks unavailable to public investors. While its groundbreaking advancements in brain-machine interfaces spark significant interest, the company remains funded by private backers, with no public IPO date announced yet. Elon Musk remains the majority shareholder. For those keen on investing in neurotechnology, alternatives like Amgen, AstraZeneca, and ARK Genomic Revolution ETF offer publicly traded options.

Frequently Asked Questions

Got More Questions? We've Got Answers:
A Guide to Commonly Asked FAQs.

No items found.